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Insulin resistanceObesity, themetabolic syndrome (MetS), and type 2 diabetes (T2DM) are associatedwith heightened cardiovas-
cular risk. Given the vasoconstrictor and proatherogenic properties of endothelin (ET)-1, increased ET-1 activity
has been postulated to participate in the derangement of adiposity-related vascular homeostasis. This concept is
supported by human studies using receptor antagonists to show that the activity of endogenous ET-1 is indeed
enhanced in overweight and obesity, the MetS, and T2DM. Also, increased ET-1 contributes to endothelial dys-
function related to obesity, the MetS, and T2DM, whereas decreasing ET-1 vasoconstrictor tone in these patients
corrects the defective endothelium-dependent vasodilation. In addition, in patients with central adiposity and
the MetS, enhanced intravascular ET-1 activity coexists with decreased nitric oxide (NO)-dependent vasodilator
capacity, suggesting a prevalence of vasoconstrictor mediators in vessels of obese individuals. One mechanism
evoked to explain the development of vascular abnormalities in obesity deals with the derangement of the phys-
iological vascular effects of insulin in insulin-resistant states. Thus, in conditions of adiposity, defective insulin-
mediated vasodilation leads to impaired ability of the hormone to enhance its delivery and that of substrates
to peripheral tissues. An important role of ET-1 in this abnormality is supported by studies showing that upreg-
ulation of the ET-1 system impairs NO-mediated vasodilation in insulin-resistant patients, whereas NO bioactiv-
ity is restored following ET-1 antagonism. In conclusion, considerable evidence supports amechanistic role of ET-1
in the pathophysiology of adiposity-related vascular dysfunction. Targeting the ET-1 system, therefore,might have
the potential for effective cardiovascular prevention in obesity, the MetS, and T2DM.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The metabolic syndrome (MetS), deﬁned as a cluster of elevated
blood pressure, abnormal fasting blood glucose (FBG), and atherogenic
dyslipidemia, represents the major metabolic and cardiovascular com-
plication of central obesity (Grundy et al., 2004), being associated with
an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascularthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
150 U. Campia et al. / Life Sciences 118 (2014) 149–155events (Alberti et al., 2009). The impact of the ongoing worldwide epi-
demic of obesity (Haslam and James, 2005) and obesity-related MetS
on the incidence and prevalence of T2DM is dramatically evident in
theUnited States,where, using theAmericanDiabetes Association crite-
rion of FBG ≥ 126 mg/dL, 1.9 million new cases are diagnosed every
year and 19.7 million people≥ 20 years of age had diabetes in 2010, re-
spectively (American Heart Association, 2013). The links between obe-
sity, the MetS, T2DM, and cardiovascular disease have been the focus of
intense investigation. Numerous lines of research suggest that arterial
endothelial dysfunction, through a decreased bioavailability of the vaso-
dilator and anti-inﬂammatory molecule nitric oxide (NO) and an in-
creased vascular activity of the vasoconstrictor and mitogenic peptide
endothelin (ET)-1, plays a pivotal role in the pathogenesis of insulin
resistance, hypertension, and vascular damage observed in these condi-
tions (Campia et al., 2012). As themechanisms underlying the activation
of the ET-1 system are being unraveled, its contribution to endothelial
dysfunction, insulin resistance, and atherosclerosis is gaining recogni-
tion. A thorough understanding of this signaling pathway could have im-
portant clinical implications, as it may lead to the identiﬁcation of new
therapeutic targets to reduce the cardiometabolic risk in these patients.
In this manuscript we will summarize the current knowledge re-
garding the activation of the ET-1 system in the blood vessels of patients
with obesity, the MetS, and T2DM; we will examine the available evi-
dence concerning changes in insulin signaling as a mechanisms of
increased ET-1 activity in these patients; and ﬁnally, wewill review cur-
rent and future perspectives of therapies based on ET-1 antagonism in
cardiovascular prevention.
The vascular endothelin system and endothelial dysfunction in
obesity, metabolic syndrome, and type 2 diabetes
The arterial endothelium exerts a central control on the mainte-
nance and modulation of vascular tone (Barac et al., 2007). In the
healthy state, endothelial cells continuously produce NO and other va-
sodilator molecules, thereby promoting a relaxed vascular state. How-
ever, they simultaneously synthesize and release constricting factors,
which help to modulate the tone of the vascular bed. Among them,
ET-1, one of the three members of the endothelin family and the most
potent known endothelial vasoconstrictor (Barton and Yanagisawa,
2008; Yanagisawa et al., 1988), appears to play a central pathophysio-
logical role in endothelial dysfunction. The biological actions of ET-1
are mediated by two speciﬁc receptor subtypes, known as endothelin
receptors type A (ETA) and type B (ETB) (Arai et al., 1990; Sakurai
et al., 1990). The vascular smoothmuscle expresses both ETA and ETB re-
ceptors, which elicit contraction (Haynes et al., 1995; Seo et al., 1994),
whereas only the ETB receptor is present on endothelial cells, in which
it triggers the synthesis and release of NO and prostacyclin, thereby in-
ducing endothelium-dependent smooth muscle relaxation (de Nucci
et al., 1988). Given its potent and prolonged vascular effects, an exces-
sive ET-1 bioactivity has been considered a likely contributor in the
pathogenesis of essential hypertension, vascular damage, and reduced
skeletal muscle perfusion leading to insulin resistance (Barton and
Yanagisawa, 2008). The initial investigations on the pathophysiologic
roles of ET-1 in humans focused on the measurement of circulating
levels of the peptide in various disease states. While elevated plasma
ET-1 concentrationwhere reported by some groups in patients with hy-
pertension (Kohno et al., 1990; Saito et al., 1990), obesity, MetS (Ferri
et al., 1997), and T2DM (Mangiaﬁco et al., 1998), these ﬁndings were
not consistently reproduced (Guvener et al., 1997), questioning the va-
lidity of this approach. This evidencemay be explained by experimental
data suggesting that endothelial ET-1 secretion occurs mainly toward
themedial layer (Wagner et al., 1992), consistentwithmostly paracrine
and autocrine, rather than endocrine, effects. In addition, circulating ET-1
levels may be affected by the degree of its clearance, including renal,
receptor- or enzyme-mediated, andmay not be an accuratemarker of en-
dothelial ET-1 production. Luckily, the availability of highly selective ETAand ETB receptor antagonists has allowed a more accurate assessment of
the contribution of ET-1 to vascular tone maintenance in the human vas-
culature in vivo. Therefore, our group and other laboratories have used
these pharmacological tools to investigate the vascular responses to the
selective and the nonselective blockade of ET-1 receptors, as well as to
the administration of exogenous ET-1, in healthy individuals and in pa-
tients with various cardiovascular and metabolic risk factors. In the fol-
lowing paragraphs, we will review the main ﬁndings of those studies
and their impact on our understanding of the vascular ET-1 system in
obesity and obesity-related metabolic disorders.
After demonstrating an increased ET-1-dependent vasoconstrictor
tone in patients with hypertension (Cardillo et al., 1999a) and hyper-
cholesterolemia (Cardillo et al., 2000) we expanded our investigation
to T2DM (Cardillo et al., 2002). Our ﬁndings showed that selective ETA
receptor blockade with BQ-123 results in vasodilation of the forearm
circulation in type 2 diabetics. As we did not observe this effect in
healthy controls, we concluded that ETA-dependent vasoconstrictor ac-
tivity is enhanced also in T2DM (Fig. 1, left panel). In order to gain a
mechanistic insight as towhether the elevated ETA-dependent vasocon-
strictor tone in diabetes is related to increased availability of ET-1 at the
ETA receptor level, as opposed to an enhanced arterial sensitivity to the
effects of ET-1, we compared the vascular responses to exogenous ET-1
infusion in patients and controls. In contrast with our observation in hy-
pertensive patients (Cardillo et al., 1999a), ET-1-mediated vasoconstric-
tion was less marked in diabetics than in normoglycemic participants
(Fig. 1, right panel). As the response to norepinephrine infusion was
similar in the two groups, an impaired reactivity to vasoconstrictor
stimuli did not seem to account for our ﬁndings in diabetics, suggesting
that ETA receptor downregulation due to an increased ET-1 production
is the probable underlying mechanism. Finally, to assess whether dual
ETA/B blockade with BQ-123 and BQ-788 could provide additional he-
modynamic beneﬁt over selective ETA blockade, in a subgroup of our di-
abetic cohort we compared the vasodilator response to BQ-123 alone
and to the combined infusion of BQ-123 and BQ-788. As vasodilation
was similar during selective ETA antagonism and nonselective ETA/B
blockade, the latter does not appear to afford a signiﬁcant hemodynam-
ic beneﬁt compared with ETA blockade alone. These data are consistent
with a neutral overall contribution of ETB receptors on endothelial and
smooth muscle cells in patients with diabetes, implying either that ETB
receptor retain their normal function or that receptor up- or down-
regulation occurs simultaneously in both cell types. In agreement with
our observations, Mather and co-workers reported that ETA receptor
blockade induced a signiﬁcant reduction in leg vascular resistance
both in obese individuals and in patients with T2DM, compared with
lean controls (Mather et al., 2002). Furthermore, endothelium depen-
dent vasodilation tomethacholine amongobese and type 2 diabetic par-
ticipants was signiﬁcantly ameliorated during ETA blockade, supporting
a pathophysiological role of ET-1 in the impairment of endothelial vaso-
dilator responses. Of note, these authors observed no difference in the ef-
fect of ETA blockade between obese and type 2 diabetic participants,
suggesting that ET-1-mediated vasoconstriction is increased in insulin-
resistant states such as obesity and T2DM. Based on the above evidence
indicating that obesity is associatedwith increased vascular ET-1 activity
andonour previousﬁndings of enhanced ETA-mediated vasoconstriction
in hypertensive patients (Cardillo et al., 1999a), we designed a study to
investigate whether enhanced ET-1 activity in hypertensive patients is
related to increased body mass (Cardillo et al., 2004). Our main ﬁndings
showed that overweight and obese patients had a signiﬁcant vasodilator
response to ETA blockade, whereas lean hypertensive participants did
not. In contrast, BQ-123 administration did not determine any signiﬁcant
hemodynamic changes in normotensive controls, irrespective of their
body mass. Of note, a signiﬁcant association was observed between
BQ-123-induced vasodilation and BMI in patients with hypertension
but not in normotensive controls, thereby indicating a selective enhance-
ment of ETA-mediated vasoconstriction in the former group. This abnor-
mal ETA-dependent vascular response in the presence of hypertension
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Fig. 1. Effects of ETA receptor blockade with BQ-123 (left panel) and of exogenous endothelin-1 (right panel) on forearm blood ﬂow in control subjects and patients with type 2 diabetes.
Modiﬁed from Cardillo et al., 2002.
151U. Campia et al. / Life Sciences 118 (2014) 149–155and elevated BMImay be secondary either to increased availability of ET-
1 at the ETA receptor level or to enhanced vasoconstrictor responsiveness
to ET-1. To gain amore precisemechanistic insight, we then assessed the
response to exogenous ET-1 in our study groups. As the vasoconstrictor
response in the obese normotensive participants did not differ from
that observed in the obese hypertensive group, our results indicate that
ET-1-mediated vasoconstriction in obesity is independent of blood pres-
sure values and hence suggest that enhanced ET-1 synthesis is the likely
mechanism underlying the increased ETA-dependent tone in obese hy-
pertensive patients.
In a more recent investigation, we assessed whether also patients
with a diagnosis of theMetS according to the AHA/NHLBI criteria present
enhanced vascular ET-1 activity (Tesauro et al., 2009). Consistent with
previous results in patients with various insulin resistant states, ETA an-
tagonism with BQ-123 elicits a signiﬁcantly higher vasodilator response
in patients with the MetS than in controls (Fig. 2, left panel), conﬁrming
that an enhanced ET-1 vasoconstriction tone is present in these patients.
In addition, NO synthase inhibition with L-NMMA during ETA receptor
blockadewas associatedwith lower vasodilator response in theMetS pa-
tients than in controls (Fig. 2, right panel), consistent with impaired NO
bioactivity in the vasculature of these patients.
To further expand the understanding of ET-1 system activation in
obesity, Weil and colleagues recently conducted an investigation to as-
sess if ET-1-mediated vasoconstrictor tone is elevated in overweight0 10 20 30 40 50
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Fig. 2. Effects of ETA receptor blockade with BQ-123 (left panel) and of nitric oxide synthesis inh
with obesity-related metabolic syndrome.
Modiﬁed from Tesauro et al., 2009.and obese adults independent of other cardiovascular risk factors and,
if so, to determinewhether the enhanced vascular ET-1 activity contrib-
utes to the impairment in endothelium-dependent vasodilation in these
two populations (Weil et al., 2011). Consistent with the main hypothe-
ses, the overweight and obese participants showed a blunted forearm
vasoconstrictor response to exogenous ET-1 compared with those with
normalweight; also, selective ETA receptor blockade induced a signiﬁcant
forearm vasodilator response in the overweight and obese groups but not
in the lean participants; and ﬁnally, selective ETA receptor blockade in-
creased endothelium-dependent vasodilation in the overweight and
obese patients to levels similar to those of lean controls. Thus, these
ﬁndings indicate that vascular ET-1 activity is elevated in overweight
and obesity and participates in the impaired endothelium-dependent
vasodilation observed in these conditions.
As described above, the use of intravascular ET-1 receptor blockers
allows the investigation of the role of ET-1 in the acute regulation of vas-
cular tone in various pathophysiologic conditions. In addition, the avail-
ability of oral ET-1 antagonists gives the opportunity to assess the effects
of long termET-1 receptor blockade on endothelial function and onother
markers of vascular function. In a recently published paper, Rafnsson and
colleagues reported the results of a placebo-controlled, double-blind
study designed to test the hypothesis that bosentan, a non-selective
ETA/B antagonist improves endothelial function in type 2 diabetics with
microalbuminuria (Rafnsson et al., 2012). After enrollment in the60
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sistance, such as obesity (bottom). PVAT indicates perivascular adipose tissue; NEFA, non-
esteriﬁed fatty acids; and Ox Str, oxidative stress.
152 U. Campia et al. / Life Sciences 118 (2014) 149–155study, patients were randomized to bosentan, at a dose of 125 mg twice
daily, or placebo for four weeks. Microvascular endothelium-dependent
vasodilatation (assessed as digital reactive hyperemia index) and ﬂow-
mediated dilation (FMD) of the brachial artery were measured at base-
line and at the end of treatment. Compared with placebo, treatment
with bosentan signiﬁcantly increased the reactive hyperemia index, but
not FMD, suggesting that chronic nonselective ET-1 receptor blockade
improves microvascular function, but not conduit vessel responses, in
patients with T2DM and microalbuminuria.
Taken together, the experimental evidence collected to date by our
and other laboratories strongly and consistently indicates that the ET-
1 system is activated in the presence of obesity, the MetS, and T2DM.
This phenomenon results predominantly, but not exclusively, in an in-
creased ETA-dependent vasoconstrictor tone and is associated with im-
paired NO bioactivity, hence leading to abnormal vascular function in
patients with these conditions.
Mechanisms of ET-1 system activation in obesity-related disorders:
role of vascular insulin resistance
In vitro evidence indicates that insulin exerts complex regulatory ac-
tions on ET-1 secretion and ET-gene (edn1) transcription. In cultured
endothelial cells, insulin acutely stimulates ET-1 secretion through
MAPK-dependent signaling pathways (Potenza et al., 2005) while up-
regulating ET-1 gene expression through PI3K-dependent inactivation
of GSK3β. Interestingly, activation of endothelial insulin signaling also
leads to PI3K/PDK/Akt-dependent endothelial NO synthase phosphory-
lation, with enhanced synthesis of NO and inhibition of ET-1 production
(Ohkita et al., 2002). The pathophysiological signiﬁcance of this com-
plex regulation has been the object of intense investigation. Our group
ﬁrst demonstrated this effect in-vivo in the forearm circulation of
healthy volunteers. In our experiments, no effects on baseline forearm
blood ﬂow were observed during dual ETA/B receptor antagonisms
with BQ-123 and BQ-788 or insulin infusion in the brachial artery. How-
ever, we observed a signiﬁcant vasodilation when ETA/B receptor block-
ade was superimposed to forearm hyperinsulinemia, indicating an
enhanced ET-1-dependent forearm vasoconstrictor tone. In addition,
in the presence of ETA/B receptor antagonism, the vasoconstrictor re-
sponse to L-NMMA, a competitive inhibitor of NO synthesis, was signif-
icantly higher during hyperinsulinemia than at baseline, indicating an
increased NO bioavailability (Cardillo et al., 1999b). Our ﬁndings sug-
gest that, physiologically, insulin triggers the endothelial release of
bothNO and ET-1 in the skeletalmuscle circulation. However, no hemo-
dynamic response to the hormone is observed due to the equilibrium
present between these opposing vasoactive stimuli. Our hypothesis is
consistent with the experimental ﬁndings from Vicent and colleagues,
who reported lower mRNA levels for eNOS and ET-1 in endothelial
cells obtained from knockout mice lacking the vascular endothelial
cell insulin receptor (Vicent et al., 2003). In addition to that, our more
recent work suggests that insulin physiologically acts on vascular
smoothmuscle cells to sensitize them tovasodilator stimuli through dif-
ferent mechanisms (Schinzari et al., 2010) (Fig. 3, top panel). A speciﬁc
impairment of the PI3K pathway with sparing of the MAPK-dependent
signaling cascade has been reported in insulin resistant patients with
obesity or T2DM (Cusi et al., 2000). This abnormality has relevant path-
ophysiological implications particularly in the hyperinsulinemic milieu
associated with insulin resistance. Thus, elevated insulin levels may
lead to overstimulation of the normally functioning MAPK-dependent
pathways, without a comparable effect on the abnormal PI3K cascade.
At the level of the endothelium, this would promote ET-1 synthesis in
the presence of blunted NO production (Fig. 3, bottom panel), leading
to endothelial dysfunction and enhanced vascular tone (Kim et al.,
2006). In agreement with this hypothesis, Mather and colleagues
showed both impaired endothelial reactivity to methacholine and
increased ET-1-dependent vasoconstrictor tone in obese and type 2 di-
abetic patients. Furthermore, ET-1 activity was noted to be a causalfactor in the blunted endothelial vasodilator mechanisms observed in
these patients (Mather et al., 2002).
Insulin exerts its metabolic actions also by regulating substrate de-
livery in the circulation (Baron and Clark, 1997) and this mechanism
is accomplished through insulin-induced NO synthesis by the vascular
endothelium (Muniyappa et al., 2007). Therefore, conditions associated
with an impaired endothelial vasodilator response to insulin may de-
crease substrate delivery and promote insulin resistance. Several lines
of evidence indicate that ET-1 may contribute to insulin resistance
through multiple mechanisms, including impairment of insulin signal-
ing (Ishibashi et al., 2001). These in vitro ﬁndings have been conﬁrmed
by studies in humans, in whom ET-1 infusion induces insulin resistance
asmeasured by hyperinsulinemic euglycemic glucose clamp (Ottosson-
Seeberger et al., 1997). Subsequent evidence indicates that also endog-
enous ET-1may contribute to the impaired insulin sensitivity present in
obese individuals, as ETA receptor antagonism with BQ-123 leads to a
marked increase in leg glucose uptake in response to insulin (Lteif
et al., 2007). In partial agreement with these observations, Ahlborg
and colleagues reported that combined ETA/B receptor antagonism, but
not selective ETA receptor blockade, acutely increases total body glucose
uptake and insulin sensitivity in obese patients with coronary artery
disease (Ahlborg et al., 2007). In a subsequent investigation, Shemyakin
and colleagues demonstrated that dual ETA/B receptor blockade en-
hances basal and insulin-stimulated glucose uptake also in insulin resis-
tant sedentary men. Additionally, using tissue from skeletal muscle
biopsies (rectus abdominis) from eight subjects without any metabolic
153U. Campia et al. / Life Sciences 118 (2014) 149–155disorders, these authors showed that ET-1 directly impairs glucose up-
take in skeletal muscle cells via a receptor-dependent mechanism, sug-
gesting that ET-1 regulates glucose metabolism via receptor-
dependent mechanisms in insulin resistant subjects (Shemyakin
et al., 2010).
Adipose tissue dysfunction and increased endothelin-1 activity
Over the last two decades, it has become apparent that the adipose
tissue synthesizes a number of active mediators, collectively known as
adipokines, that exert both local autocrine/paracrine actions and sys-
temic endocrine effects on distant organs and tissues (Mohamed-Ali
et al., 1998). Adipokines are involved in numerous physiological pro-
cesses, including the regulation of vascular tone. In obesity and related
disorders, the expansion of visceral adipose tissue is associated with
an abnormal synthesis of vasoactive adipokines (Hajer et al., 2008). In
addition, this dysfunctional adipose tissue releases into the bloodstream
increased amounts of nonesteriﬁed fatty acids (NEFA), as well as a vari-
ety of proinﬂammatory cytokines, thereby leading to low-grade system-
ic inﬂammatory state and to impaired vascular homeostasis due to
enhanced activity of the ET-1 system. Thus, inﬂammatory cytokines,
such as TNF-α and IL-1β, are known to increase edn1 transcription in
vascular endothelial cells (Stow et al., 2011). Similarly, increased NEFA
plasma levels have long been known to induce activation of the ET-1
system (Piatti et al., 1996). More recent evidence suggests that NEFA
might also enhance insulin-mediated ET-1 release, hence implicating a
role of ET-1 as a potentialmediator of NEFA-induced vascular insulin re-
sistance (Inyard et al., 2009). Also, in diabetes and insulin resistance, ac-
tivation of ET-1 may result from protein kinase C activation induced by
high glucose concentrations (Rask-Madsen and King, 2005). In addition
to thesemechanisms, elevated circulating levels of leptin, the product of
the ob gene, in obese patients (Considine et al., 1996) have been postu-
lated to contribute to vascular damage, as higher plasma leptin concen-
trations are associated with cardiovascular risk (Wallace et al., 2001).
The notion that hyperleptinemia might exert vasculotoxic effects
through activation of the ET-1 systemhas stemmed from studies showing
that leptin upregulates ET-1 synthesis in endothelial cells (QuehenbergerHealthy State
NO ET-1
Insulin
Signaling
Lean
Adipocytes PVAT
Dominant Relaxation,
Preserved Vascular Function
Fig. 4. In the healthy state, insulin and adipokines originating from both visceral and perivascu
and endothelin (ET)-1. ET-1 is an autocrine stimulus for endothelial production NO via ETB rece
syndrome [MetS] and type 2 diabetes [T2D]), vascular insulin resistance (I.R.), visceral adiposity
tweenNO and ET-1. Also, the reciprocal regulation between the ET-1 system and the NO pathw
and atherosclerosis.et al., 2002) and increases expression of ETA receptors in vascular smooth
muscle cells (Juan et al., 2008). However, these concepts are not support-
ed by the results of a recent work in our laboratory, designed to compare
the effects of exogenous leptin on vascular NO and ET-1 activity in lean
subjects and patients with theMetS (Schinzari et al., 2013). As previously
reported, in the absence of exogenous leptinwe observed increased ET-1-
mediated vasoconstrictor tone and impaired bioavailability of NO in the
forearm vasculature of patients with the MetS compared with controls.
In lean, normoleptinemic participants, hyperleptinemia augmented ET-
1-dependent vasoconstrictor activity and enhanced NO-dependent vaso-
dilator tone during ETA receptor antagonism. By contrast, we observed no
effects of exogenous leptin infusion on both ET-1-mediated vasoconstric-
tion and NO-dependent vasodilation in our hyperleptinemic patients
with obesity-related MetS. Taken together, our ﬁndings suggest the exis-
tence of leptin resistance in themicrocirculation of patients with obesity-
related MetS and do not support the hypothesis of detrimental vascular
effect induced by chronic hyperleptinemia.
A further mechanism potentially involved in the increased ET-1 ac-
tivity of insulin resistant patients is hypoadiponectinemia (Weyer
et al., 2001), as suggested by the evidence that, in an animal model,
adiponectin inhibits the vasoconstriction produced by ET-1 via a NO-
dependent pathway (Bussey et al., 2011). Therefore, it is reasonable to
postulate that decreased plasma adiponectin levels might also result
in enhanced ET-1-dependent vasoconstrictor tone in patients with obe-
sity and type 2 diabetes.
Following the identiﬁcation and investigation of the systemic and
vascular effects of adipocyte-derived factors, more recently also fat de-
posits around arterial vessels have been fully recognized as regulators
of vascular function (Yudkin et al., 2005) (Fig. 3, top panel). Following
the seminal in vitro observation that perivascular adipose tissue
(PVAT) regulates the contractile vascular response to norepinephrine
(Soltis and Cassis, 1991), Löhn and colleagues demonstrated that periad-
ventitial fat inhibits the vasoconstrictor response to a series of different
contractile agents (Lohn et al., 2002). In addition, Gao and colleagues
demonstrated that PVAT releases a diffusible mediator that exerts
anticontractile effects by inducing endothelial NO release (Gao
et al., 2007). Interestingly, the vasoactive effects of PVAT observedObesity, MetS, T2D
NO
ET-1
Vascular
I. R.
Visceral
Adiposity
PVAT
Hypertrophy
Dominant Constriction,
Vascular Dysfunction/Damage
lar adipocytes contribute to vascular homeostasis via a balance between nitric oxide (NO)
ptors, NO inhibits in turn ET-1 production. In obesity and related disorders (the metabolic
and perivascular adipose tissue (PVAT) hypertrophy result in intravascular imbalance be-
ay is less efﬁcient. As a consequence, enhanced ET-1 activity results in vascular dysfunction
154 U. Campia et al. / Life Sciences 118 (2014) 149–155in experimental models have also been reported in humans, both in
medium-sized arteries (Gao et al., 2005) and small arteries (Greenstein
et al., 2009).
In human obesity, as in animal models of the disease, there is an in-
crease of PVATmass due to both adipocyte expansion and proliferation.
As in visceral adipose tissue, PVAT hypertrophy secondary to obesity is
associatedwith lower capillary density, reduced partial oxygen pressure,
and an inﬂammatory phenotype (Pasarica et al., 2009), promoting oxida-
tive stress and imbalance in the production of different adipokines. In
particular, Greenstein and colleagues isolated small arteries from subcu-
taneous gluteal fat biopsies taken from healthy controls and from MetS
patients, and studied them with wire myography in the presence or
the absence of PVAT (Greenstein et al., 2009). These authors demonstrat-
ed that, physiologically, PVAT surrounding small arteries secretes one or
more vasodilator molecules that increase NO bioavailability. As incuba-
tion with an adiponectin 1 receptor blocker completely abolished the
anticontractile responses of PVAT, adiponectin likely represents one of
the factors diffusing from the PVAT. Of interest, PVAT fromMetS patients
did not exert vasodilator effects and was characterized by increased ad-
ipocyte area and by high expression of TNF-α receptor 1, a marker of
inﬂammation. Furthermore, an abnormal phenotype similar to that ob-
served in theMetS could be reproduced by treating PVAT around healthy
blood vessels with TNF-α or IL-6, a phenomenon that was abolished in
the presence of cytokine antagonism and scavenging of free radicals.
These ﬁndings indicate obese PVAT-derived ROS and inﬂammatory cyto-
kinesmay adverselymodulate vascular function. It is still unclearwheth-
er alterations of PVAT in obesity are concurrent or rather follow those of
visceral adipose tissue. However, as themediators involved are the same
as those released by visceral fat, it is reasonable to assume that PVAT dys-
function in obesitymay affect vascular homeostasis by activating the ET-
1 system (Fig. 3, bottom panel). This notion is further supported by the
results of recent studies showing that chemerin, an adipokinemediating
the vasoconstrictor effects of obese PVAT (Watts et al., 2013), acts to in-
crease ET-1-induced arterial contraction via activation of MAPK and
ERK1/2 (Lobato et al., 2012).
Therapeutic applications of ET-1 antagonism
In the quarter century since its discovery, our understanding of the
role of the ET-1 system in cardiovascular physiology and pathophysiol-
ogy has steadily grown and has led to the development of a new class of
oral ET-1 receptor antagonists. While the initial enthusiasm for the use
of these drugs to treat highly prevalent diseases, such as hypertension
and heart failure, has been mitigated by lack of clinical efﬁcacy, ET-1
receptor blockers have becomeﬁrst line treatment for less common dis-
orders, such as various forms of pulmonary hypertension. Preclinical ev-
idence suggests that numerous conditions characterized by cell growth
and inﬂammatory activation, such as diabetic nephropathy, may beneﬁt
from treatment with ET-1 receptor blockers. While a clinical trial using
avosentan, a likely nonselective ETA/B receptor antagonist, showed a re-
duction of albuminuria in these patients, the study had to be stopped
early because of signiﬁcant safety concerns related to ﬂuid retention
(Mann et al., 2010). However, a more recent trial demonstrated that
atrasentan, a selective ETA antagonist, is safe and efﬁcacious in treating
residual albuminuria in patients with T2DM on stable doses of RAS in-
hibitors, suggesting a potentially better safety proﬁle of selective versus
nonselective receptor antagonism (Kohan et al., 2011).
Summary and conclusions
Vascular ET-1 system activity is enhanced in the vasculature of pa-
tientswith obesity, theMetS, and T2DM. This activation is likely second-
ary to abnormalities in vascular insulin signaling, as well as to changes
in visceral and perivascular fat pads, and may contribute in and of itself
to the pathogenesis of both insulin resistance and vascular dysfunction/
damage (Fig. 4). In clinical studies, blockade of ET-1 receptors hasshown the potential to enhance insulin sensitivity and slow the progres-
sion of nephropathy. Further investigation is necessary tomore effectively
and safely exploit the beneﬁts of ET-1 antagonism for cardiovascular pre-
vention in these patients.
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